Dr. Karl Petri is establishing a research group at the University Hospital Würzburg to develop and enhance novel CRISPR 2.0 tools for generating and improving cancer-targeted CAR-T cell products.
CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the USA and a year later in Europe for treating acute lymphoblastic leukemia (ALL). For instance, no effective CAR-T cell therapies for solid tumors exist. Furthermore, CAR-T-induced remissions are not always durable, and the production of CAR-T cells is slow and laborious.
Dr. ...
